A5049977777- Sustainability and Ecological Systems Analysis
- Sustainable Development and Environmental Policy
- Global Energy and Sustainability Research
- Cognitive Science and Mapping
- Land Use and Ecosystem Services
- Agriculture Sustainability and Environmental Impact
- Sustainable Agricultural Systems Analysis
- Coastal wetland ecosystem dynamics
- Soil and Water Nutrient Dynamics
- Advanced Thermodynamics and Statistical Mechanics
- Peatlands and Wetlands Ecology
- Virus-based gene therapy research
- Environmental Impact and Sustainability
- Complex Systems and Decision Making
- Genomics and Phylogenetic Studies
- Environmental Conservation and Management
- Aquatic Ecosystems and Phytoplankton Dynamics
- Constructed Wetlands for Wastewater Treatment
- Urban Stormwater Management Solutions
- Corporate Social Responsibility Reporting
- Water-Energy-Food Nexus Studies
- Microbial Community Ecology and Physiology
- Ecology and Vegetation Dynamics Studies
- Ecosystem dynamics and resilience
- Environmental Sustainability in Business
University of Florida
2015-2024
University of the Sunshine Coast
2017-2022
Beijing Normal University
2019-2021
State Key Joint Laboratory of Environment Simulation and Pollution Control
2019-2021
BI Norwegian Business School
2010-2020
Pfizer (United States)
2020
University of Oxford
2017
Institute of Geographic Sciences and Natural Resources Research
2017
Florida Museum of Natural History
2013
University of California, Los Angeles
2004-2011
We describe the genome sequence of protist Trichomonas vaginalis , a sexually transmitted human pathogen. Repeats and transposable elements comprise about two-thirds ∼160-megabase genome, reflecting recent massive expansion genetic material. This expansion, in conjunction with shaping metabolic pathways that likely transpired through lateral gene transfer from bacteria, amplification specific families implicated pathogenesis phagocytosis host proteins may exemplify adaptations parasite...
Objective Tanezumab, a nerve growth factor inhibitor, was investigated for osteoarthritis (OA) of the hip or knee in study with 24-week treatment and safety follow-up. Methods This double-blind, randomised, phase III enrolled adults Europe Japan moderate-to-severe OA who had not responded to could tolerate standard-of-care analgesics. Patients were randomised tanezumab 2.5 mg 5 subcutaneously matching placebo every 8 weeks (three doses). Co-primary end points change from baseline week 24...